These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 33086081)

  • 1. Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on iron regulation in non-dialysis-dependent chronic kidney disease patients with anemia: A systematic review and meta-analysis.
    Li J; Xie QH; You L; Xu NX; Hao CM
    Pharmacol Res; 2021 Jan; 163():105256. PubMed ID: 33086081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors
    Yang J; Xing J; Zhu X; Xie X; Wang L; Zhang X
    Front Endocrinol (Lausanne); 2023; 14():1131516. PubMed ID: 37008953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of hypoxia-inducible factor-prolyl hydroxylase inhibitors on anemia in patients with CKD: a meta-analysis of randomized controlled trials including 2804 patients.
    Wang B; Yin Q; Han YC; Wu M; Li ZL; Tu Y; Zhou LT; Wei Q; Liu H; Tang RN; Cao JY; Lv LL; Liu BC
    Ren Fail; 2020 Nov; 42(1):912-925. PubMed ID: 32869703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages.
    Mima A
    Eur J Pharmacol; 2021 Dec; 912():174583. PubMed ID: 34678238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease.
    Kurata Y; Tanaka T; Nangaku M
    Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):414-422. PubMed ID: 32452915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease.
    Chen J; Shou X; Xu Y; Jin L; Zhu C; Ye X; Mei Z; Chen P
    Aging (Albany NY); 2023 Mar; 15(6):2237-2274. PubMed ID: 36988549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Patients with Renal Anemia: A Meta-Analysis of Randomized Trials.
    Wen T; Zhang X; Wang Z; Zhou R
    Nephron; 2020; 144(11):572-582. PubMed ID: 32866960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors versus erythropoiesis-stimulating agents on iron metabolism and inflammation in patients undergoing dialysis: A systematic review and meta-analysis.
    Zheng Q; Zhang P; Yang H; Geng Y; Tang J; Kang Y; Qi A; Li S
    Heliyon; 2023 Apr; 9(4):e15310. PubMed ID: 37123954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac and Kidney Adverse Effects of HIF Prolyl-Hydroxylase Inhibitors for Anemia in Patients With CKD Not Receiving Dialysis: A Systematic Review and Meta-analysis.
    Zheng Q; Wang Y; Yang H; Sun L; Zhang P; Zhang X; Guo J; Liu YN; Liu WJ
    Am J Kidney Dis; 2023 Apr; 81(4):434-445.e1. PubMed ID: 36396085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
    Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
    Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) on anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD): a systematic review and meta-analysis.
    Zhang S; Guo J; Xie S; Chen J; Yu S; Yu Y
    Int Urol Nephrol; 2021 Jun; 53(6):1139-1147. PubMed ID: 33026571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
    Souza E; Cho KH; Harris ST; Flindt NR; Watt RK; Pai AB
    Expert Opin Investig Drugs; 2020 Aug; 29(8):831-844. PubMed ID: 32476498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta-analysis including 13,146 patients.
    Chen H; Cheng Q; Wang J; Zhao X; Zhu S
    J Clin Pharm Ther; 2021 Aug; 46(4):999-1009. PubMed ID: 33615523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis.
    Zheng Q; Yang H; Sun L; Wei R; Fu X; Wang Y; Huang Y; Liu YN; Liu WJ
    Pharmacol Res; 2020 Sep; 159():105020. PubMed ID: 32561478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Kidney Disease.
    Ha JT; Hiremath S; Jun M; Green SC; Wheeler DC; Coyne DW; Perkovic V; Badve SV
    NEJM Evid; 2024 Sep; 3(9):EVIDoa2300189. PubMed ID: 39186635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease.
    Akizawa T; Macdougall IC; Berns JS; Yamamoto H; Taguchi M; Iekushi K; Bernhardt T
    Nephron; 2019; 143(4):243-254. PubMed ID: 31387097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A spotlight on using HIF-PH inhibitors in renal anemia.
    Odawara M; Nishi H; Nangaku M
    Expert Opin Pharmacother; 2024 Jul; 25(10):1291-1299. PubMed ID: 38994698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in patients with chronic kidney disease: meta-analysis of phase 3 randomized controlled trials.
    Minutolo R; Liberti ME; Simeon V; Sasso FC; Borrelli S; De Nicola L; Garofalo C
    Clin Kidney J; 2024 Jan; 17(1):sfad143. PubMed ID: 38186871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors.
    Sugahara M; Tanaka T; Nangaku M
    Pharmacol Ther; 2022 Nov; 239():108272. PubMed ID: 36031160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors and Iron Metabolism.
    Ogawa C; Tsuchiya K; Maeda K
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.